PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Supplementation with 250 mg/d of beta-1,3/1,6-glucan in older adults (50-70 years) reduced the occurrence of medically confirmed URTIs compared to placebo (17 vs 28 episodes) [PMID:28606567].
In stressed women, 250 mg of Wellmune daily for 12 weeks resulted in fewer upper respiratory symptoms (10% vs 29%) and improved global mood state compared to placebo [PMID:23378458].
A phase I exploratory study indicated that yeast beta-glucan supplementation lowers insulin resistance without altering microbiota composition [PMID:39439317].
Safety & adverse effects
Dosage & administration
Evidence summary
PubMed sources
- 1.PMID: 7002086 (1980) — Saccharomyces cerevisiae septicemia. · Archives of internal medicine
- 2.PMID: 24677744 (2014) — Advances in metabolic engineering of yeast Saccharomyces cerevisiae for production of chemicals. · Biotechnology journal
- 3.PMID: 28606567 (2017) — Yeast-derived β-1,3/1,6 glucan, upper respiratory tract infection and innate immunity in older adults. · Nutrition (Burbank, Los Angeles County, Calif.)
- 4.PMID: 30925027 (2019) — Yeast Systems Biology: Model Organism and Cell Factory. · Biotechnology journal
- 5.PMID: 39439317 (2024) — Yeast β-glucan supplementation lowers insulin resistance without altering microbiota composition compared with placebo in subjects with type II diabetes: a phase I exploratory study.